RU2651469C1 - Лечение рака - Google Patents
Лечение рака Download PDFInfo
- Publication number
- RU2651469C1 RU2651469C1 RU2016140271A RU2016140271A RU2651469C1 RU 2651469 C1 RU2651469 C1 RU 2651469C1 RU 2016140271 A RU2016140271 A RU 2016140271A RU 2016140271 A RU2016140271 A RU 2016140271A RU 2651469 C1 RU2651469 C1 RU 2651469C1
- Authority
- RU
- Russia
- Prior art keywords
- tumor
- cells
- axitinib
- density
- percentage
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 129
- 238000011282 treatment Methods 0.000 title claims abstract description 40
- 201000011510 cancer Diseases 0.000 title claims abstract description 21
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 claims abstract description 160
- 102100025136 Macrosialin Human genes 0.000 claims abstract description 160
- 230000014509 gene expression Effects 0.000 claims abstract description 65
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 claims abstract description 54
- 229960003005 axitinib Drugs 0.000 claims abstract description 49
- 229920001184 polypeptide Polymers 0.000 claims abstract description 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 10
- 230000035945 sensitivity Effects 0.000 claims abstract description 10
- 238000000034 method Methods 0.000 claims description 65
- 238000003364 immunohistochemistry Methods 0.000 claims description 29
- 206010050513 Metastatic renal cell carcinoma Diseases 0.000 claims description 18
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 6
- 208000020816 lung neoplasm Diseases 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 5
- 208000037841 lung tumor Diseases 0.000 claims description 5
- 201000002528 pancreatic cancer Diseases 0.000 claims description 5
- 238000010191 image analysis Methods 0.000 claims description 4
- 238000013388 immunohistochemistry analysis Methods 0.000 claims description 3
- 239000003814 drug Substances 0.000 abstract description 10
- 238000005259 measurement Methods 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 4
- 238000002560 therapeutic procedure Methods 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 139
- 210000002540 macrophage Anatomy 0.000 description 69
- 108090000623 proteins and genes Proteins 0.000 description 63
- 239000003550 marker Substances 0.000 description 40
- 239000000090 biomarker Substances 0.000 description 39
- 102000004169 proteins and genes Human genes 0.000 description 38
- 238000004458 analytical method Methods 0.000 description 35
- 239000000523 sample Substances 0.000 description 34
- 229940124674 VEGF-R inhibitor Drugs 0.000 description 26
- 210000001519 tissue Anatomy 0.000 description 26
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 25
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 20
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 19
- LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 description 18
- 230000004044 response Effects 0.000 description 18
- 229940034785 sutent Drugs 0.000 description 18
- 238000012360 testing method Methods 0.000 description 18
- 108020004999 messenger RNA Proteins 0.000 description 16
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 12
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 11
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 11
- 102100034184 Macrophage scavenger receptor types I and II Human genes 0.000 description 10
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 9
- 101001134216 Homo sapiens Macrophage scavenger receptor types I and II Proteins 0.000 description 9
- 238000002493 microarray Methods 0.000 description 9
- 108010009992 CD163 antigen Proteins 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 8
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 8
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 8
- 102100025831 Scavenger receptor cysteine-rich type 1 protein M130 Human genes 0.000 description 8
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 8
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 8
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- 238000002123 RNA extraction Methods 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 208000037821 progressive disease Diseases 0.000 description 7
- 108090000144 Human Proteins Proteins 0.000 description 6
- 102000003839 Human Proteins Human genes 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 238000002405 diagnostic procedure Methods 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- 239000000092 prognostic biomarker Substances 0.000 description 6
- 238000003753 real-time PCR Methods 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 238000000018 DNA microarray Methods 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 238000011529 RT qPCR Methods 0.000 description 5
- 238000010240 RT-PCR analysis Methods 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000012188 paraffin wax Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 239000000107 tumor biomarker Substances 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 102100034343 Integrase Human genes 0.000 description 4
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000002349 favourable effect Effects 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 230000009871 nonspecific binding Effects 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 206010061818 Disease progression Diseases 0.000 description 3
- 101000777599 Homo sapiens C-C chemokine receptor type 2 Proteins 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 208000006265 Renal cell carcinoma Diseases 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 230000005750 disease progression Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 229940005319 inlyta Drugs 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- -1 methylcarbamoyl Chemical group 0.000 description 3
- 210000000066 myeloid cell Anatomy 0.000 description 3
- 239000002547 new drug Substances 0.000 description 3
- 208000019465 refractory cytopenia of childhood Diseases 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 229960001796 sunitinib Drugs 0.000 description 3
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 101150029707 ERBB2 gene Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 239000013614 RNA sample Substances 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 239000004037 angiogenesis inhibitor Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 229960000397 bevacizumab Drugs 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229960003787 sorafenib Drugs 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 229960000575 trastuzumab Drugs 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 101100446590 Arabidopsis thaliana FIM5 gene Proteins 0.000 description 1
- 241000713838 Avian myeloblastosis virus Species 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 101150106011 FIM2 gene Proteins 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102100022338 Integrin alpha-M Human genes 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- 101710134306 Macrophage scavenger receptor types I and II Proteins 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241000714177 Murine leukemia virus Species 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
- 241000589500 Thermus aquaticus Species 0.000 description 1
- 238000013103 analytical ultracentrifugation Methods 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229920000547 conjugated polymer Polymers 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000013211 curve analysis Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001861 endoscopic biopsy Methods 0.000 description 1
- 238000007387 excisional biopsy Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000007386 incisional biopsy Methods 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000012332 laboratory investigation Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007762 localization of cell Effects 0.000 description 1
- 238000010841 mRNA extraction Methods 0.000 description 1
- 238000000681 mass spectrometry of recoiled ion Methods 0.000 description 1
- 238000010339 medical test Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 description 1
- 238000013188 needle biopsy Methods 0.000 description 1
- 238000013059 nephrectomy Methods 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 229940124617 receptor tyrosine kinase inhibitor Drugs 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 238000011519 second-line treatment Methods 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004960 subcellular localization Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 229960000235 temsirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000006711 vascular endothelial growth factor production Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Mycology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461983951P | 2014-04-24 | 2014-04-24 | |
| US61/983,951 | 2014-04-24 | ||
| PCT/IB2015/052796 WO2015162532A1 (en) | 2014-04-24 | 2015-04-16 | Cancer treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2651469C1 true RU2651469C1 (ru) | 2018-04-19 |
Family
ID=53398149
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016140271A RU2651469C1 (ru) | 2014-04-24 | 2015-04-16 | Лечение рака |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US20170184602A1 (enExample) |
| EP (1) | EP3134119B1 (enExample) |
| JP (1) | JP6603474B2 (enExample) |
| KR (1) | KR101943177B1 (enExample) |
| CN (1) | CN106233143B (enExample) |
| AR (1) | AR100169A1 (enExample) |
| AU (3) | AU2015249513A1 (enExample) |
| BR (1) | BR112016024143A2 (enExample) |
| CA (1) | CA2946362C (enExample) |
| CY (1) | CY1120731T1 (enExample) |
| DK (1) | DK3134119T3 (enExample) |
| ES (1) | ES2691213T3 (enExample) |
| HU (1) | HUE040167T2 (enExample) |
| IL (1) | IL247859B (enExample) |
| MX (1) | MX375794B (enExample) |
| PL (1) | PL3134119T3 (enExample) |
| PT (1) | PT3134119T (enExample) |
| RU (1) | RU2651469C1 (enExample) |
| SG (1) | SG11201607918TA (enExample) |
| SI (1) | SI3134119T1 (enExample) |
| TR (1) | TR201815682T4 (enExample) |
| TW (1) | TWI568439B (enExample) |
| WO (1) | WO2015162532A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6945199B2 (ja) | 2017-05-19 | 2021-10-06 | 国立大学法人山口大学 | アキシチニブの薬物動態判定方法及びアキシチニブの薬物動態に基づくアキシチニブによる治療効果予測方法 |
| WO2020014666A1 (en) * | 2018-07-12 | 2020-01-16 | Corvus Pharmaceuticals, Inc. | Methods for detecting and treating cancers having adenosine pathway activation |
| US12174192B2 (en) | 2018-07-12 | 2024-12-24 | Corvus Pharmaceuticals, Inc. | Methods for detecting and treating cancers having adenosine pathway activation |
| US10936768B2 (en) * | 2018-10-15 | 2021-03-02 | Aible, Inc. | Interface for visualizing and improving model performance |
| US10586164B1 (en) | 2018-10-15 | 2020-03-10 | AIble Inc. | Interface for visualizing and improving model performance |
| WO2021076852A1 (en) * | 2019-10-17 | 2021-04-22 | Board Of Regents, The University Of Texas System | Small extracellular vesicle-associated vegf as a predictor for therapeutic responses |
| JP2025518483A (ja) * | 2022-05-11 | 2025-06-17 | ドイチェス クレブスフォルシュンクスツェントルム スチフトゥング デス エッフェントリヒェン レヒツ | 肺癌のための診断マーカーとしてのｂｍｍｆ１ ｒｅｐタンパク質の使用 |
| JP2025518482A (ja) * | 2022-05-11 | 2025-06-17 | ドイチェス クレブスフォルシュンクスツェントルム スチフトゥング デス エッフェントリヒェン レヒツ | 膵臓癌および２型糖尿病のための診断マーカーとしてのｂｍｍｆ１ ｒｅｐタンパク質の使用 |
| WO2024026407A1 (en) * | 2022-07-28 | 2024-02-01 | The Board Of Regents Of The University Of Oklahoma | Biomarkers, diagnostic methods, treatments, and therapeutics for autoimmune disorders and diseases |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2395090C2 (ru) * | 2005-10-21 | 2010-07-20 | БАЙЕР ХелсКер ЛЛСи | Способы прогнозирования и предсказания рака и мониторинг терапии раковых заболеваний |
| RU2480769C2 (ru) * | 2006-07-28 | 2013-04-27 | Новартис Аг | Применение белка с меланома-ингибирующей активностью (миа) в качестве раннего индикатора терапевтического ответа при меланоме |
| US20140018375A1 (en) * | 2005-03-16 | 2014-01-16 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors |
| US20140045715A1 (en) * | 2009-10-19 | 2014-02-13 | Aveo Pharmaceuticals, Inc. | Tivozanib response prediction |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004284434A1 (en) | 2003-10-16 | 2005-05-06 | Genomic Health, Inc. | qRT-PCR assay system for gene expression profiling |
| CA2848463A1 (en) * | 2004-04-09 | 2005-10-27 | Genomic Health, Inc. | Gene expression markers for predicting response to chemotherapy |
| US20070128636A1 (en) * | 2005-12-05 | 2007-06-07 | Baker Joffre B | Predictors Of Patient Response To Treatment With EGFR Inhibitors |
| CA2669531A1 (en) * | 2006-11-22 | 2008-06-05 | University Of Georgia Research Foundation, Inc. | Tyrosine kinase inhibitors as anti-kinetolastid and anti-apicomplexan agents |
| EA021945B1 (ru) * | 2009-07-08 | 2015-10-30 | Уорлдуайд Иновейтив Нетуорк | Способ прогнозирования эффективности лекарственных соединений для пациента |
| WO2011033006A1 (en) * | 2009-09-17 | 2011-03-24 | F. Hoffmann-La Roche Ag | Methods and compositions for diagnostics use in cancer patients |
| WO2012052757A1 (en) * | 2010-10-20 | 2012-04-26 | Astrazeneca Ab | Tumour phenotype patient selection method |
| JP2014503500A (ja) * | 2010-11-18 | 2014-02-13 | シンタ ファーマスーティカルズ コーポレーション | 低酸素状態に基づく酸素感受性薬剤による治療に適した被験体の事前選択 |
| EP2763680A4 (en) * | 2011-10-04 | 2015-05-20 | Invivis Pharmaceuticals Inc | METHODS AND SYSTEMS FOR IDENTIFYING AND TREATING ANTIPROGESTIN-SENSITIVE TUMORS |
| EP2802346B1 (en) * | 2012-01-13 | 2018-09-12 | F.Hoffmann-La Roche Ag | Biological markers for identifying patients for treatment with vegf antagonists |
-
2015
- 2015-04-16 EP EP15729222.8A patent/EP3134119B1/en not_active Not-in-force
- 2015-04-16 HU HUE15729222A patent/HUE040167T2/hu unknown
- 2015-04-16 CN CN201580021401.8A patent/CN106233143B/zh not_active Expired - Fee Related
- 2015-04-16 MX MX2016013910A patent/MX375794B/es active IP Right Grant
- 2015-04-16 CA CA2946362A patent/CA2946362C/en not_active Expired - Fee Related
- 2015-04-16 ES ES15729222.8T patent/ES2691213T3/es active Active
- 2015-04-16 TR TR2018/15682T patent/TR201815682T4/tr unknown
- 2015-04-16 PT PT15729222T patent/PT3134119T/pt unknown
- 2015-04-16 DK DK15729222.8T patent/DK3134119T3/en active
- 2015-04-16 WO PCT/IB2015/052796 patent/WO2015162532A1/en not_active Ceased
- 2015-04-16 AU AU2015249513A patent/AU2015249513A1/en not_active Abandoned
- 2015-04-16 US US15/305,066 patent/US20170184602A1/en not_active Abandoned
- 2015-04-16 SI SI201530426T patent/SI3134119T1/sl unknown
- 2015-04-16 RU RU2016140271A patent/RU2651469C1/ru active
- 2015-04-16 BR BR112016024143A patent/BR112016024143A2/pt not_active Application Discontinuation
- 2015-04-16 SG SG11201607918TA patent/SG11201607918TA/en unknown
- 2015-04-16 PL PL15729222T patent/PL3134119T3/pl unknown
- 2015-04-16 KR KR1020167029131A patent/KR101943177B1/ko not_active Expired - Fee Related
- 2015-04-22 JP JP2015087291A patent/JP6603474B2/ja not_active Expired - Fee Related
- 2015-04-23 AR ARP150101225A patent/AR100169A1/es unknown
- 2015-04-23 TW TW104113043A patent/TWI568439B/zh not_active IP Right Cessation
-
2016
- 2016-09-16 IL IL247859A patent/IL247859B/en active IP Right Grant
-
2018
- 2018-05-03 AU AU2018203086A patent/AU2018203086A1/en not_active Abandoned
- 2018-10-05 CY CY181101033T patent/CY1120731T1/el unknown
-
2019
- 2019-03-01 US US16/290,827 patent/US20190331687A1/en not_active Abandoned
-
2020
- 2020-01-13 AU AU2020200237A patent/AU2020200237A1/en not_active Abandoned
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140018375A1 (en) * | 2005-03-16 | 2014-01-16 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors |
| RU2395090C2 (ru) * | 2005-10-21 | 2010-07-20 | БАЙЕР ХелсКер ЛЛСи | Способы прогнозирования и предсказания рака и мониторинг терапии раковых заболеваний |
| RU2480769C2 (ru) * | 2006-07-28 | 2013-04-27 | Новартис Аг | Применение белка с меланома-ингибирующей активностью (миа) в качестве раннего индикатора терапевтического ответа при меланоме |
| US20140045715A1 (en) * | 2009-10-19 | 2014-02-13 | Aveo Pharmaceuticals, Inc. | Tivozanib response prediction |
Non-Patent Citations (4)
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2651469C1 (ru) | Лечение рака | |
| EP2764364B1 (en) | Predicting tumor response to anti-erbb3 antibodies | |
| US7736861B1 (en) | Tivozanib response prediction | |
| HK1231561B (zh) | 癌症治疗 | |
| HK1200530B (en) | Predicting tumor response to anti-erbb3 antibodies |